lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer

Xu, Mu; Chen, Xiaoxiang; Kang, Lin; Zeng, Ke; Liu, Xiangxiang; Xu, Xueni; Pan, Bei; Xu, Tan; Sun, Li; He, Bangshun; Pan, Yuqin; Sun, Huiling; Wang, Shukui

doi:10.1186/s13045-018-0690-5

Cited by 172 publications

(160 citation statements)

References 46 publications

Supporting

Mentioning

153

Contrasting

Order By: Relevance

“…Moreover, SNHG6 acts as the sponges of microRNAs (miRNAs) to participate in the pathogenesis of multiple malignancies. Accumulating evidence shows that SNHG6 acts as an oncogenic factor by sponging miR‐4465 in ovarian clear cell carcinoma and miR‐181a‐5p/−miR‐26a/b/−214 in CRC . These studies indicate that SNHG6 can mediate miRNA networks to participate in cancer progression.…”

Section: Introductionmentioning

confidence: 88%

Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p

Jiang

Xiang

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background: The aim of this study was to determine the function of long noncoding RNA small nucleolar RNA host gene 6 (SNHG6) in non-small cell lung cancer (NSCLC) and its underlying mechanisms. Methods: The association of SNHG6 or miR-101-3p with clinicopathological characteristics and prognosis in patents with NSCLC was assessed by TCGA dataset. Cell proliferation and invasion were evaluated by MTT and Transwell assays and SNHG6-specific binding with miR-101-3p was verified by bioinformatic analysis, luciferase gene report and RNA immunoprecipitation assays. qRT-PCR and Western blot was used to assess the effects of SNHG6 on the expression of miR-101-3p and chromodomain Y like (CDYL) in NSCLC cells. A xenograft tumor model in vivo was established to observe the effects of SNHG6 knockdown on tumor growth. Results: We found that increased expression of SNHG6 was associated with pathological stage and lymph node infiltration, and acted as an independent prognostic factor of tumor recurrence in patients with NSCLC. Silencing SNHG6 expression repressed cell growth and invasion in vitro and in vivo, but overexpression of SNHG6 reversed these effects. Furthermore, SNHG6 was identified to act as a sponge of miR-101-3p, which could reduce cell proliferation and attenuate SNHG6-induced CDYL expression. Low expression of miR-101-3p or high expression of CDYL was related to poor survival in patients with NSCLC. Conclusions: Our findings demonstrated that lncRNA SNHG6 contributed to the proliferation and invasion of NSCLC by downregulating miR-101-3p.

show abstract

Section: Introductionmentioning

confidence: 88%

Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p

Jiang

Xiang

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…The lncRNA CRNDE was shown to promote CRC cell proliferation and chemoresistance by regulating miR-181a-5p in vitro [17]. The lncRNA SNHG6 was reported to promote CRC cell growth, migration, and invasion both in vitro and in vivo by interacting with miR-26a, miR-26b, and miR-214 and regulating their common target EZH2 [18].…”

mentioning

confidence: 99%

The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p

et al. 2020

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs) have been shown to participate in multiple biological processes and confer drug resistance. However, it remains unclear whether lncRNAs are involved in conferring cetuximab resistance in colorectal cancer (CRC) cells.Methods: Cell Counting Kit-8 (CCK-8) assays were performed to assess the sensitivity of CRC cell lines to cetuximab treatment. -2 cells were stably transduced with cetuximab resistance-associated RNA transcript 16 (CRART16) or an empty vector using lentiviral infection; the cells were designated Caco-2-CRART16 and Caco-2-NC, respectively, and were analyzed with RNA sequencing (RNA-seq). Quantitative real-time PCR (qRT-PCR) was performed to investigate RNA expression. Flow cytometry and TUNEL assays were used to assess apoptosis levels induced by cetuximab. The cell cycle, stemness biomarkers and membrane proteins of CRC cells were assessed via flow cytometry. RNA fluorescence in situ hybridization (FISH) was used to examine CRART16 localization and expression. Bioinformatics analysis was performed to predict the potential mechanism of CRART16, which was further validated by a dual-luciferase reporter assay. Differences in measurement data were compared using Student's t test, one-way ANOVA followed by Dunnett's test and two-way ANOVA.

show abstract

“…All of the included studies were performed in China and were published from 2016 to 2019 with a mean sample size of 71. In terms of the type of cancer, 5 studies referred to colorectal cancer [10][11][12][13][14], 2 studies related to glioma [15,26], 2 studies involved osteosarcoma [16,27], and the remaining cohorts were on ovarian cancer [18], lung cancer [19], oesophageal cancer [20], gastric cancer [21], and liver cancer [22]. Of the 14 studies included, 6 had survival dates in the original literature, and the survival dates for the others were determined with graphical survival plots following the published method proposed by Tierney et al [28].…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

“…With the development of high-throughput RNA sequencing techniques and bioinformatic algorithms, a spectrum of lncRNAs have been identified. The small nucleolar RNA host gene 6 (SNHG6; also termed U87HG), a subclass of lncRNA molecules, pervasively participates in gene modulation through functioning as an oncogene in different human cancers, including colorectal cancer [10][11][12][13][14], glioma [15], osteosarcoma [16], breast cancer [17], ovarian cancer [18], lung adenocarcinoma [19], oesophageal cancer [20], gastric cancer [21] and liver cancer [22]. Studies have proven that the upregulation of SNHG6 plays multiple critical roles in cell differentiation, proliferation, apoptosis, and multidrug resistance [23,24].…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of SNHG6 in human cancers: a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Recently, accumulating evidence has suggested that the aberrant expression of SNHG6 exists in a variety of tumors and has a correlation with poor clinical outcomes across cancer patients. Considering the inconsistent data among published studies, we aim to assess the prognostic effect of SNHG6 on malignancies. Methods: We retrieved relevant publications in Web of Science, Embase, MEDLINE, PubMed and Cochrane Library based on predefined selection criteria, up to October 1, 2019. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were utilized to evaluate the correlation between SNHG6 and overall survival (OS), recurrence-free survival (RFS) and progression-free survival (PFS) as well as clinicopathology.Results: In total, 999 patients from 14 articles were enrolled in our meta-analysis. The results revealed that augmented SNHG6 expression was significantly correlated with poor OS (HR = 2.20, 95% CI = 1.76-2.75, P < 0.001) and RFS (HR = 3.10, 95% CI = 1.90-5.07, P < 0.001), but not with PFS (HR = 2.11, 95% CI = 0.82-5.39, P = 0.120). In addition to lung cancer and ovarian cancer, subgroup analysis showed that the prognostic value of SNHG6 across multiple tumors was constant as the tumor type, sample size, and methods of data extraction changed. Moreover, cancer patients with enhanced SNHG6 expression were prone to advanced TNM stage (OR = 3.31, 95% CI = 2.46-4.45, P < 0.001), distant metastasis (OR = 4.67, 95% CI = 2.98-7.31, P < 0.001), lymph node metastasis (OR = 2.59, 95% CI = 1.41-4.77, P = 0.002) and deep tumor invasion (OR = 3.75, 95% CI = 2.10-6.69, P < 0.001), but not associated with gender, histological grade and tumor size.Conclusions: SNHG6 may serve as a promising indicator in the prediction of prognosis and clinicopathological features in patients with different kinds of tumors.

show abstract

lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer

Cited by 172 publications

References 46 publications

Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p

Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p

The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p

Prognostic and clinicopathological significance of SNHG6 in human cancers: a meta-analysis

Contact Info

Product

Resources

About